Ariad Pharmaceuticals, Inc. Announces Recommendation of Data Monitoring Committee Following Second Interim Analysis of Phase 3 Succeed Trial of Oral Ridaforolimus, an Investigational mTOR Inhibitor, in Metastatic Sarcomas

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the independent Data Monitoring Committee (DMC) of the Phase 3 SUCCEED trial has completed the second interim efficacy analysis as specified in the study protocol and has recommended that the randomized, placebo-controlled trial of oral ridaforolimus in patients with metastatic sarcomas continue to its final analysis, without modification to the study protocol.